BioPharmSignal logoBioPharmSignal

Biotech News

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

Lenz Therapeutics Inc (LENZ)Lenz Therapeutics IncPartnership

LENZ (LENZ) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is lenz.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

LENZLenz Therapeutics Inc2026-06-24 12:30 EST

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

LENZLenz Therapeutics Inc2026-01-14 13:30 EST

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

LCTXLineage Cell Therapeutics2026-01-06 13:00 EST

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

IRIXIRIDEX2026-04-07 20:05 EST

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

LCTXLineage Cell Therapeutics2025-11-24 16:20 EST

Lineage Achieves First Milestone Under Worldwide Collaboration Agreement with Genentech

KPRXKiora Pharmaceuticals2025-10-30 13:00 EST

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

TARSTarsus Pharmaceuticals2026-05-14 12:30 EST

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

MGTXMeiraGTx2025-11-10 12:00 EST

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

OTLKOutlook2026-02-19 14:00 EST

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

VRDNViridian Therapeutics2022-01-04 12:00 EST

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

View all latest news

Lenz Therapeutics Inc

LENZ Therapeutics is an ophthalmology company focused on presbyopia and eye-care treatments. Its story is centered on bringing a differentiated eye-health product to a large but competitive market.

Recent company news

LENZLenz Therapeutics Inc2026-07-06 12:15 EST

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

LENZLenz Therapeutics Inc2026-06-24 12:30 EST

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

LENZLenz Therapeutics Inc2026-06-07 23:30 EST

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

LENZLenz Therapeutics Inc2026-05-26 12:00 EST

LENZ Therapeutics to Participate in Upcoming Investor Conferences

LENZLenz Therapeutics Inc2026-05-11 20:05 EST

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Stock data

Close
5.70 USD
Market cap
223.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States